Anti-PD-1 matches interferon as adjuvant therapy for acral melanoma: a retrospective study
Therapeutic Advances in Medical Oncology · 2026-04 · 18
DOI: 10.1177/17588359261436189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 22.04.2026. Verfasst von Yu Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University C…. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, Beijing Research Ward Excellence Program, natural science foundation of beijing municipality.
Abstract (Originalsprache)
Background
Programmed cell death protein (PD-1) inhibitors constitute the standard adjuvant therapy for cutaneous melanoma (CM), but well-established strategies for acral melanoma (AM) remain limited.
Objective
To compare the efficacy of adjuvant anti-PD-1 immunotherapy versus high-dose interferon α-2b (HDI) in patients with stage IIB-IV AM and CM.
Design
This multicenter, retrospective study enrolled 511 patients with resected stage IIB-IV AM and CM between January 2017 and December 2023.
Methods
Patients were divided into four groups by subtype and treatment: patients with CM and treated with anti-PD-1 (CM-PD-1), patients with CM and treated with HDI (CM-HDI), patients with AM and treated with anti-PD-1 (AM-PD-1), and patients with AM and treated with HDI (AM-HDI). Recurrence-free survival (RFS), overall survival (OS), and patient safety were evaluated.
Results
This study comprised 362 AM and 149 CM cases. AM cases presented with thicker primary lesions, higher ulceration rates, and fewer BRAF mutations. Median follow-up was 49 months. Among patients with stage IIB/C, median RFS was not reached in any groups. Among stage III/IV patients, median RFS was 14.6 (CM-PD-1), 13.7 (CM-HDI), 13.3 (AM-PD-1), and 11.7 months (AM-HDI), and median OS was 61.6, 40.7, 42.4, and 53.4 months, respectively, without significant intergroup differences. Anti-PD-1 significantly improved RFS in patients with stage III/IV AM with KIT mutations (9.1 vs 5.0 months, p = 0.048) and ⩾4 lymph node metastases (10.5 vs 6.6 months, p = 0.036). Anti-PD-1 had significantly fewer adverse effects than HDI (60.4% vs 88.6%, p < 0.001), including fewer grades 3–4 events (4.6% vs 30.7%, p < 0.001).
Conclusion
Adjuvant anti-PD-1 therapy provides RFS comparable to that of HDI in AM and CM, with a superior safety profile. Patients with AM harboring KIT mutations derive greater benefits from adjuvant anti-PD-1 therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
- Department of Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China.
- Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China.
ORCID-Profile: Yu Du
Förderung
- National Key Research and Development Program of China
- Beijing Research Ward Excellence Program
- natural science foundation of beijing municipality
- Beijing Municipal Administration of Hospitals’ Ascent Plan
Zitieren
APA
Du, Y., Chen, Y., Wang, J., Lin, J., Wei, X., Gu, J., Guo, J., Si, L., & Mao, L. (2026). Anti-PD-1 matches interferon as adjuvant therapy for acral melanoma: a retrospective study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261436189
Vancouver
Du Y, Chen Y, Wang J, Lin J, Wei X, Gu J, et al. Anti-PD-1 matches interferon as adjuvant therapy for acral melanoma: a retrospective study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261436189
BibTeX
@article{Du2026,
author = {Du, Yu and Chen, Yu and Wang, Jiaxiang and Lin, Jing and Wei, Xiaoting and Gu, Junjie and Guo, Jun and Si, Lu and Mao, Lili},
title = {Anti-PD-1 matches interferon as adjuvant therapy for acral melanoma: a retrospective study},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261436189}
}
EUVIMED